FDA Approves OraVerse for Younger Pediatric Dental Patients

Posted: June 20, 2016
Edited by Dentaltown staff

LANCASTER, Penn.—Septodont announced that the United States Food and Drug Administration (FDA) has approved the change of the minimum age for OraVerse (Phentolamine Mesylate) from 6 years old to 3 years old.  The approval came as the result of a phase IV, multicenter, randomized, double-blind, controlled study for the safety and efficacy of OraVerse in pediatric patients ages three to five.  

OraVerse rapidly reverses the lingering numbness of the lip and tongue from local dental anesthetic and is administered by the dentist immediately following routine procedures such as a filling or crown prep. Busy people who need to return to their jobs, kids who tend to chew their numb lips and cheeks, and diabetics who need to eat following a procedure are the types of individuals who can benefit greatly from OraVerse.

OraVerse is manufactured by Septodont and is available for purchase through a dental dealer.
 
Sponsors
Townie Perks
Townie® Poll
Have you ever switched practice management platforms for your practice?
  
Sally Gross, Member Services Specialist
Phone: +1-480-445-9710
Email: sally@farranmedia.com
©2024 Dentaltown, a division of Farran Media • All Rights Reserved
9633 S. 48th Street Suite 200 • Phoenix, AZ 85044 • Phone:+1-480-598-0001 • Fax:+1-480-598-3450